NCT06400888尚未招募不适用
a Prospective, Randomized, Open-Label, Clinical Trial Study Comparing the Efficacy and Safety for Needle-Free Subcutaneous Injector and Conventional Intramuscular Injection of Mecobalamin in Diabetes Peripheral Neuropathy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 30
- 主要终点
- corneal confocal microscopy parameter: inferior whorl length
研究概览
简要总结
The evaluation for efficacy and safety of needle-free subcutaneous injector and conventional intramuscular injection of mecobalamin for diabetic neuropathy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subjects, age 18-70 years.
- •Participants who have been diagnosed with type 1 or type 2 diabetes for at least 1 year.
- •Meet the diagnosis of peripheral neuropathy according to neuroelectrophysiological examination.
- •According to the researchers' clinical judgment, blood glucose has been optimally controlled. The blood glucose was kept as stable as possible during the study. HbA1c level≤9% prior to screening, the variety is at least less than 2% within the 3-months before enrollment.
- •No history of eye trauma or corneal laser treatment.
- •No history of keratopathy or other intraocular ophthalmic disease.
- •No history of wearing contact lenses.
- •Have not taken medicines that affect corneal metabolism.
- •Did not take Mecbl or α-lipoic acid therapy within 3 months before screening.
- •Women of child bearing age (e.g., non-operative birth control or pausimenia less than 1 year) must be negative in the gonadotropin pregnancy test (urine) screening and receive effective contraception during treatment.
- •Signs the informed consent.
- •Subjects are willing and able to comply with the study visit schedule, treatment plan, laboratory tests and other study procedures.
排除标准
- •Have been diagnosed with a malignant tumor in the past 2 years.
- •The presence of other neurological disorders that researchers believe perhaps affect the evaluation of DPN.
- •The presence of skin diseases in the affected skin areas may affect the evaluation of DPN and injection according to the researcher's judgment.
- •Amputation of the ends of fingers and toes.
- •Participated in any other trials involving a study or post-marketing drug within 30 days of screening.
- •Subjects with clinically significant or unstable diseases, such as but not limited to acute cardiovascular diseases, cerebrovascular diseases, liver diseases, kidney diseases, respiratory diseases, blood diseases, immune system diseases, inflammatory or rheumatic diseases, uncontrolled infections, symptomatic peripheral vascular diseases, untreated endocrine diseases, etc.
- •Had donated blood within 30 days of the study treatment commencement (if applicable); or preparative blood donors during the study or 30 days after the end of treatment.
- •The WBC < 4000 / mm^2, neutrophils count <1500/mm^2, platelet count <100×109 /mm^
- •Clinically significant abnormalities in 12-lead ECG.
- •Subjects received combining transcutaneous electrical nerve stimulation (TENS) or acupuncture.
- •A history of intolerance or allergy to Mecbl or similar chemical compound.
- •Current or history presence of alcohol and/or other substance abuse within the past 1 year.
- •Other severe acute or chronic medical or psychiatric conditions or laboratory abnormalities that, in the determination of the investigator, may increase the risk associated with participating in the trial or using Mecbl, or that may affect the interpretation of the study results, may render the subject unfit to participate in the trial.
- •Inability and/or unwillingness to understand and/or comply with the plan.
结局指标
主要结局
corneal confocal microscopy parameter: inferior whorl length
时间窗: baseline, 8 weeks
The corneal nerve fiber length in inferior whorl area.
corneal confocal microscopy parameter: corneal nerve fiber length
时间窗: baseline, 8 weeks
The corneal nerve fiber length per frame.
concentration of plasma vitamin B12
时间窗: baseline, half an hour, first hour, second hour, 8 weeks
The plasma vitamin B12, biomarker for effective active metabolite for neural repair.
次要结局
- neurological function scales score: Norfolk Quality of Life Questionnaire - Diabetic Neuropathy (QOL-DN)(baseline, 8 weeks)
- neurological function scales score: Neuropathy Impairment Score (NIS)(baseline, 8 weeks)
- neurological function scales score: the modified Toronto clinical neuropathy score (mTCNS)(baseline, 8 weeks)
- neurological function scales score: Neuropathy Impairment Score of the lower limbs plus seven tests (NIS(LL)+7 tests)(baseline, 8 weeks)
- neuroelectrophysiological parameter: NCV(baseline, 8 weeks)
- neurological function scales score: NDS score(baseline, 8 weeks)
- neurological function scales score: Polyneuropathy disability (PND) score(baseline, 8 weeks)
- neurological function scales score: DNS score(baseline, 8 weeks)
- neuroelectrophysiological parameter: SSR(baseline, 8 weeks)
研究者
Yuanjin Zhang
Chief Physician of Department of Neurology
Peking University Third Hospital
相似试验
未知
3 期
Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis (STATURE)JPRN-jRCT2080221733ovartis Pharma K.K.
尚未招募
3 期
Comparison of efficacy and safety of two modes of Autologous Serum Therapy injectioCTRI/2024/02/062280Mythraye B
未知
3 期
An open-label study of subcutaneous injection (s.c.) S-811717 (oxycodone hydrochloride solution for injection) in patients with cancer paiJPRN-jRCT2080220763SHIONOGI & CO., LTD.
已完成
3 期
A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing SpondylitisSpondylitis, AnkylosingNCT00265083Centocor, Inc.356
进行中（未招募）
1 期
/AEUCTR2018-003427-11-ESProbelte Pharma S.L.U.350